IRCT20180404039187N9招募中3 期
The study of efficacy of Empagliflozin on metabolic effects of atypical antipsychotic drugs in patients with psychiatric disorders: a randomized clinical trial
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Aged 18 - 65 years old
- •Diagnosis of mental disorders with psychosis and psychotic disorders based on DSM-V-TR
- •Stable treatment with atypical antipsychotics (olanzapine, clozapine and risperidone) in the last 6 months (no dose change in the last 30 days)
- •Stable body weight (definition: less than 5% weight change in the last three months before the trial)
- •Body mass index greater than or equal to 25 (BMI=25)
排除标准
- •Pregnancy and lactation
- •A recent history of drug abuse or dependence
- •Hepatic failure (increase in liver trans aminases to 2 times normal)
- •Renal insufficiency (GFR less than 30)
- •Having type 1 or 2 diabetes
- •Dysfunction of the pancreas
- •Cardiovascular disease
- •Uncontrollable blood pressure
- •Treatment with corticosteroids or other hormone therapy
- •Use medication to lose weight in the last 3 months
研究者
相似试验
已完成
1 期
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
招募中
2 期
SGLT2 Inhibition with Empagliflozin on Metabolic, Cardiac and Renal Outcomes in Recent Cardiac Transplant RecipientsCardiac transplantRenal diseaseCardiovascular - Other cardiovascular diseasesMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseDiabetesACTRN12622000978763Garvan Institute of Medical Research100
已完成
3 期
The effect of empagliflozin laboratory findingsCondition 1: Diabetes Mellitus type 2. Condition 2: Coronary artery disease.Type 2 diabetes mellitusAtherosclerotic heart disease of native coronary arteryI125.1IRCT20190412043247N1Zanjan University of Medical Sciences100
招募中
3 期
Effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parametersIRCT20190911044744N3Yazd University of Medical Sciences50
尚未招募
3 期
Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkersIRCT20120215009014N486Hamedan University of Medical Sciences80